Fidelity Disruptive Medicine ETFNASDAQ:FMED
- LAST PRICE24.67
- TODAY'S CHANGE (%)-0.83 (-3.25%)
- Bid / Lots21.25/ 1
- Ask / Lots30.51/ 1
- Open / Previous Close25.24 / 25.50
- Day Range
- 52 Week Range
- Volume5,247
- Overall Morningstar Rating2 out of 5 Starsout of 268 funds
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | FMED |
|---|---|---|
| 09:32 ET | 526 | 25.24 |
| 10:09 ET | 1100 | 25 |
| 10:13 ET | 198 | 25 |
| 12:50 ET | 1000 | 24.91 |
| 02:38 ET | 350 | 24.73 |
| 03:39 ET | 1213 | 24.75 |
| 04:00 ET | 1213 | 24.67 |
Daily Premium/Discount
| Date | Daily Premium/Discount |
|---|---|
| 08/20/2024 | -0.20% |
| 08/21/2024 | -0.26% |
| 08/22/2024 | -0.11% |
| 08/23/2024 | -0.14% |
| 08/26/2024 | -0.20% |
| 08/27/2024 | -0.07% |
| 08/28/2024 | -0.04% |
| 08/29/2024 | -0.14% |
| 08/30/2024 | -0.09% |
| 09/03/2024 | -0.17% |
| 09/04/2024 | -0.03% |
| 09/05/2024 | -0.24% |
| 09/06/2024 | -0.07% |
| 09/09/2024 | -0.14% |
| 09/10/2024 | 0.01% |
| 09/11/2024 | -0.28% |
| 09/12/2024 Largest Premium | 0.02% |
| 09/13/2024 | -0.10% |
| 09/16/2024 | 0.01% |
| 09/17/2024 | -0.18% |
| 09/18/2024 | -0.16% |
| 09/19/2024 | -0.24% |
| 09/20/2024 | -0.26% |
| 09/23/2024 | -0.15% |
| 09/24/2024 | -0.21% |
| 09/25/2024 | -0.23% |
| 09/26/2024 | -0.22% |
| 09/27/2024 | -0.29% |
| 09/30/2024 | -0.30% |
| 10/01/2024 | -0.03% |
| 10/02/2024 | -0.25% |
| 10/03/2024 | -0.10% |
| 10/04/2024 | -0.34% |
| 10/07/2024 | -0.19% |
| 10/08/2024 | -0.07% |
| 10/09/2024 | -0.05% |
| 10/10/2024 | -0.16% |
| 10/11/2024 | -0.15% |
| 10/14/2024 | -0.04% |
| 10/15/2024 | -0.17% |
| 10/16/2024 | -0.23% |
| 10/17/2024 | -0.04% |
| 10/18/2024 | -0.02% |
| 10/21/2024 | -0.12% |
| 10/22/2024 | -0.07% |
| 10/23/2024 | -0.08% |
| 10/24/2024 | -0.03% |
| 10/25/2024 | -0.03% |
| 10/28/2024 | -0.07% |
| 10/29/2024 | -0.16% |
| 10/30/2024 | -0.21% |
| 10/31/2024 | 0.01% |
| 11/01/2024 Largest Discount | -0.39% |
| 11/04/2024 | 0.00% |
| 11/05/2024 | -0.17% |
| 11/06/2024 | -0.30% |
| 11/07/2024 | -0.24% |
| 11/08/2024 | -0.08% |
| 11/11/2024 | -0.14% |
| 11/12/2024 | -0.11% |
| 11/13/2024 | -0.16% |
| 11/14/2024 | -0.07% |
| 11/15/2024 | -0.27% |
| US Stock | 88.4% |
|---|---|
| Non-US Stock | 10.1% |
| Cash | 5.0% |
| Convertible | 0 |
| Non-US Bond | 0 |
| Preferred | 0 |
| Healthcare | 98.4% |
|---|---|
| Basic Mat. | 0 |
| Communication Services | 0 |
| Consumer Cyclical | 0 |
| Consumer Defensive | 0 |
| Energy | 0 |
| Financial Serv.s | 0 |
| Industrials | 0 |
| Real Estate | 0 |
| Technology | 0 |
| Utilities | 0 |
| United States | 89.8% |
|---|---|
| Europe | 4.9% |
| Canada | 1.2% |
| Africa | 0 |
| Latin America | 0 |
| Asia/Oceania | 0 |
| Company Name sortable | Position sortable | Allocation sortable | Allocation sortable1 Month Change | Market Value sortable |
|---|---|---|---|---|
Boston Scientific Corp | Long | 6.0% | 0.00% | $3.3M |
UnitedHealth Group Inc | Long | 4.5% | 0.00% | $2.4M |
Intuitive Surgical Inc | Long | 4.2% | 0.00% | $2.3M |
Danaher Corp | Long | 3.9% | 0.00% | $2.1M |
Insulet Corp | Long | 3.9% | 0.00% | $2.1M |
Exact Sciences Corp | Long | 3.8% | 0.00% | $2.0M |
Regeneron Pharmaceuticals Inc | Long | 3.5% | 0.00% | $1.9M |
Fidelity Securities Lending Cash Central Fund | Long | 3.4% | +33.72% | $1.9M |
argenx SE ADR | Long | 3.3% | 0.00% | $1.8M |
Alnylam Pharmaceuticals Inc | Long | 3.0% | 0.00% | $1.6M |
Reports
- ManagedInvestmentETF11/10/24
Morningstar ETF Report
The Morningstar ETF Report offers in-depth analyst research on exchange-traded funds to help you evaluate these investments and how they fit within a portfolio.
Morningstar Ratings
| Time Horizon | Star Rating |
|---|---|
| Overall Rating | 2 out of 5 Stars |
| 3 Year Rating | 2 out of 5 Stars |
| 5 Year Rating | Not Rated |
| 10 Year Rating | Not Rated |
Past performance is no guarantee of future results. The ratings reflect historical risk-adjusted performance, and the overall rating is derived from a weight average of the fund's 3, 5, and 10 year (Morningstar Rating) metrics.
Style Box is calculated only using the long position holdings of the portfolio.
Best Fit Index | MSCI ACWI NR USD |
|---|---|
Category | |
Sponsor | Fidelity Management & Research Company LLC |
Inception | April 16, 2020 |
The investment seeks long-term growth of capital. The fund normally invests at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. The fund is non-diversified.
| Total Net Assets | $54.2M |
|---|---|
| Shares Out. | 2.1M |
| Net Asset Value (NAV) | $24.74 |
| Prem/Discount to NAV | -0.27% |
| P/E Ratio | 40.8 |
| Dividend Yield | 0.00% |
| Dividend per Share | 0.00 USD |
| Ex-Dividend Date | 06/21/2024 |
| Dividend Payment Date | 06/25/2024 |
| Beta | --- |
| Morningstar Investment Style | Health |
| Equity Style | Mid Cap Growth |
| Credit Quality / Duration | --- |
| Actual Management Fee | 0.50% |
|---|---|
| Actual Mgmt. Expense Ratio (MER) | 0.50% |